erad picture

INNOVATIVE SCIENCE

An Orphan Drug Company focusing on the treatment of Tay-Sachs Disease and neurological complications of Gaucher Disease, by delivering protein therapeutics to all cells in the body including the central nervous system.

OUR SCIENCE

OUR SYNOPSIS

ERAD Therapeutics Inc.

erad picture subpage

INNOVATIVE SCIENCE

Delivering Protein Therapeutics to the CNS for Gaucher Disease

TAY-SACHS DISEASE

Tay-Sachs is a genetic disorder caused by the absence of-hexosaminidase (HexA). This missing enzyme causes cells to become damaged, resulting in progressive neurological disorders. A definitive treatment for the symptoms of Tay-Sachs Disease does not yet exist.

There are 3 forms of Tay-Sachs:

The form is determined by the age of the individual when symptoms first appear. Only one form of Tay-Sachs occurs in a family. If a child has Infantile, older siblings are not at risk to develop Juvenile or Late Onset Tay-Sachs later in life.

Classic Infantile Tay-Sachs -Symptoms appear around 6 months of age

Juvenile Tay-Sachs -Symptoms typically appear between ages 2 and 5, but can occur anytime during childhood.

Late Onset Tay-Sachs -Symptoms typically appear in adolescence or early adulthood, but can appear later.

LEARN MORE

GAUCHER DISEASE

Gaucher Disease is the most common Lysosomal Storage Disease, yet it is still considered an Orphan Disease. Currently affecting over 8,000 American’s, it is a genetic disorder resulting in an enzyme deficiency. Type 1 disease usually results in an enlarged liver, enlarged spleen, anemia and bone disease. Without therapy this significantly impacts both the quality and duration of life. Type 3 disease impacts all of the above as well as causing progressive and ultimately fatal neurological deterioration.

LEARN MORE